CRISPR and Cas Gene Market Size - By Product & Services (Product {Kits & Enzymes, Antibodies, Libraries}, Services {Cell Line Engineering}), Application (Genome Engineering, Epigenetics), End-use, Global Forecast, 2023 - 2032

CRISPR and Cas Gene Market Size - By Product & Services (Product {Kits & Enzymes, Antibodies, Libraries}, Services {Cell Line Engineering}), Application (Genome Engineering, Epigenetics), End-use, Global Forecast, 2023 - 2032

CRISPR and Cas Gene Market Size

CRISPR and Cas Gene Market size accounted for USD 2.5 billion in 2022 and is estimated to grow at 21.7% to reach USD 17.4 billion by 2032. As the prevalence of genetic diseases and complex medical conditions continues to rise, there is an increasing demand for innovative treatments that can target the root cause of these ailments.
 

For instance, according to the Lancet Haematology report, in 2021, seaHaall-age prevalence of sickle cell disease among females and males was 3·9 million and 3·84 million respectively globally. By enabling precise and targeted modifications to DNA sequences, CRISPR allows researchers and pharmaceutical companies to develop customized gene therapy and precision medicine approaches.
 

CRISPR and Cas genes refer to gene-editing technologies used in molecular biology to modify DNA sequences with precision. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a naturally occurring genetic mechanism found in bacteria and archaea that acts as an adaptive immune system against viral infections. Whereas, cas (CRISPR-associated) genes encode for cas proteins, which function as molecular scissors, capable of cleaving specific DNA sequences.
 

COVID-19 Impact

The COVID-19 pandemic had a positive impact on the CRISPR and Cas gene market. The urgency to combat the pandemic had spurred scientists and researchers to explore innovative solutions. For instance, in March 2021, scientists from Nanyang Technological University in Singapore created a CRISPR-based coronavirus testing that produces findings in 30 minutes. The test checks the virus after it has mutated. Moreover, CRISPR technology has been leveraged in vaccine development, enabling the optimization of vaccine candidates, and facilitating more efficient vaccine production.
 

CRISPR and Cas Gene Market Trends

The increasing prevalence of cancer worldwide is anticipated to boost the industry evolution. For instance, according to the American Cancer Society, Inc. report, in 2022, there approximately more than 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the U.S. alone. Therefore, CRISPR-Cas gene editing technology offers a promising approach in the fight against cancer by enabling precise and customizable alterations to the genetic makeup of cancer cells. Moreover, ongoing advancements in gene editing techniques and a deeper understanding of cancer genetics will accelerate the adoption of CRISPR technology.
 

CRISPR and Cas Gene Market Analysis

Off-target effects refer to unintended changes or mutations in the genome that occur when the CRISPR-Cas system mistakenly targets and edits DNA sequences other than the intended target. These unintended alterations may lead to potential safety concerns and unpredictability in gene editing outcomes, impacting the efficacy and reliability of CRISPR-based applications. Furthermore, the high cost associated with CRISPR technology may hamper its adoption, particularly in smaller research institutions and organizations with limited budgets.
 

By product & services, the CRISPR and Cas gene market is classified into product and services. The product segment accounted for 78.7% of the market share in 2022. The expanding range of applications for CRISPR technology, such as genome engineering, disease model studies, and functional genomics will accelerate the industry progression. Also, the increasing government and private spending for enhancement of innovative therapies along with growing adoption of strategic initiatives by industry players.
 

Based on application, the CRISPR and Cas gene market is segmented into cell line engineering, gRNA design, microbial gene editing, DNA synthesis, and screening. The genome engineering segment accounted for 38.5% of the market share in 2022 due to increasing genomics research and development activities demonstrating the effectiveness of CRISPR technologies. For instance, in May 2021, Vertex and CRISPR Therapeutics presented new clinical data on investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for severe hemoglobinopathies at the annual European Hematology Association Virtual Congress. CTX001 underwent evaluation in two active clinical trials, with the aim of potentially providing a one-time curative treatment for patients affected by transfusion-dependent thalassemia (TDT) and severe sickle cell disease (SCD).
 

Based on end-use, the CRISPR and Cas gene market is segmented into biotechnology & pharmaceutical companies, academics & government research institutes, and contract research organizations (CROs). The biotechnology & pharmaceutical companies segment is projected to witness lucrative growth of 21.2% by 2032. The growing number of partnerships and collaborations between academic researchers and industry players is expected to foster the adoption of CRISPR technology in the development of cutting-edge treatments and innovative solutions. Also, growing investment by biotechnology companies as well as employing gene modification for both research and commercial applications.
 

North America CRISPR and Cas gene market accounted for 42.3% market share in 2022. The region's strong biotechnology and pharmaceutical sector encourages research and development in CRISPR technology for drug discovery and therapeutics. Also, increasing government funding and research grants along with well-established healthcare infrastructure & favorable regulatory environment facilitate the adoption of CRISPR in clinical trials and therapeutic applications in the region.
 

CRISPR and Cas Gene Market Share

Major market players operating in the CRISPR and Cas gene market include

• AstraZeneca plc
• Addgene 
• Cellectis
• CRISPR Therapeutics
• Editas Medicine, Inc.
   

CRISPR and Cas Gene Industry News

• In February 2023, Ensoma, a genomic medicines company acquired Twelve Bio ApS, a gene editing company pioneering the therapeutic application of next-generation CRISPR-Cas medicines. This strategy helped the company to expand its service portfolio and customer base.
   
• In May 2020, Merck has received approval for two of its CRISPR-Cas9-assisted genomes-editing patents in the U.S. This strategy helped the company to expand its customer base.
   

The CRISPR and Cas gene market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments

Click here to Buy Section of this Report

By Products & Services

• Product
  • Kits & Enzymes
    • Vector-based Cas
    • DNA-free Cas
  • Libraries
  • Design Tool
  • Antibodies
  • Other products
• Services
  • Cell Line Engineering
  • gRNA Design
  • Microbial Gene Editing
  • DNA Synthesis
  • Screening

Application

• Genome Engineering
• Disease Model Studies
• Functional Genomics
• Epigenetics
• Other Applications

End-use

• Biotechnology & Pharmaceutical Companies
• Academics & Government Research Institutes
• Contract Research Organizations (CROs)

The above information is provided for the following regions and countries

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of Middle East & Africa